The use of CD3-specific antibodies in autoimmune diabetes: A step toward the induction of immune tolerance in the clinic

Handbook of Experimental Pharmacology

Volumn 181, Issue , 2008, Pages 221-236

  Chatenoud, L ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CD3 ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL; DISEASE MODEL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNE TOLERANCE; TREATMENT OUTCOME;

EID: 38449094203     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-540-73259-4_10     Document Type: Article

References (116)

1. Abramowicz D, Schandene L et al. (1989) Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47(4):606-608
2. Adler SH, Turka LA (2002) Immunotherapy as a means to induce transplantation tolerance. Curr Opin Immunol 14(5):660-665
3. Akashi T, Nagafuchi S et al. (1997) Direct evidence for the contribution of B cells to the progression of insulitis and the development of diabetes in non-obese diabetic mice. Int Immunol 9(8):1159-1164
4. Alegre ML, Peterson LJ et al. (1994) A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57(11):1537-1543
5. Asano M, Toda M et al. (1996) Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184(2):387-396
6. Bach JF (1994) Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 15(4):516-542
7. Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347(12):911-920
8. Bach JF, Chatenoud L (2001) Tolerance to islet autoantigens and type I diabetes. Annu Rev Immunol 19:131-161
9. Baekkeskov S, Aanstoot HJ et al. (1990) Identification of the 64K autoantigen in insulindependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347(6289):151-156
10. Baxter AG, Horsfall AC et al. (1994) Mycobacteria precipitate an SLE-like syndrome in diabetesprone NOD mice. Immunology 83(2):227-231
11. Baxter AG, Mandel TE (1991) Hemolytic anemia in non-obese diabetic mice. Eur J Immunol 21(9):2051-2055
12. Belghith M, Bluestone JA et al. (2003) TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. NatMed 9(9):1202-1208
13. Bendelac A, Carnaud C et al. (1987) Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med 166(4):823-832
14. Bluestone JA, Abbas AK (2003) Natural versus adaptive regulatory T cells. Nat Rev Immunol 3(3):253-257
15. Boitard C, Yasunami R et al. (1989) T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med 169(5):1669-1680
16. Bolt S, Routledge E et al. (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 23(2):403-411
17. Bottazzo GF, Florin-christensen A et al. (1974) Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2(7892):1279-1283
18. Charlton B, Bacelj A et al. (1989) Cyclophosphamide-induced diabetes in NOD/WEHI mice. Evidence for suppression in spontaneous autoimmune diabetes mellitus. Diabetes 38(4):441-447
19. Chatenoud L (2003) CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 3(2):123-132
20. Chatenoud L, Bach JF (1984) Antigenic modulation: a major mechanism of antibody action. Immunol Today 5(1):20-25
21. Chatenoud L, Baudrihaye MF et al. (1986) Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 137(3):830-838
22. Chatenoud L, Baudrihaye MF et al. (1982) Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 12(11):979-982
23. Chatenoud L, Ferran C et al. (1990) In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49(4):697-702
24. Chatenoud L, Ferran C et al. (1989) "Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 320(21):1420-1421
25. Chatenoud L, Primo J et al. (1997) CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158(6):2947-2954
26. Chatenoud L, Thervet E et al. (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 91(1):123-127
27. Christianson SW, Shultz LD et al. (1993) Adoptive transfer of diabetes into immunodeficient NODscid/ scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 42(1):44-55
28. Clevers H, Alarcon B et al. (1988) The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol 6(1):629-662
29. Cobbold SP, Adams E et al. (1996) Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev 149:5-33
30. Cobbold SP, Qin S et al. (1992) Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev 129:165-201
31. Cosimi AB (1987) Clinical development of Orthoclone OKT3. Transplant Proc 19(2 Suppl 1):7-16
32. Cosimi AB, Burton RC et al. (1981a) Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32(6):535-539
33. Cosimi AB, Colvin RB et al. (1981b) Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 305(6):308-314
34. Crisa L, Mordes JP et al. (1992) Autoimmune diabetes mellitus in the BB rat. Diabetes Metab Rev 8(1):4-37
35. Daniel D, Gill RG et al. (1995) Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol 25(4):1056-1062
36. Dardenne M, Lepault F et al. (1989) Acceleration of the onset of diabetes in NOD mice by thymectomy at weaning. Eur J Immunol 19(5):889-895
37. Davis MM, Chien YH (1999) T cell antigen receptors. In: Paul W (ed) Fundamental immunology. Raven, New York, pp 341-366
38. Debure A, Chkoff N et al. (1988) One-month prophylactic use of OKT3 in cadaver kidney transplant recipients. Transplantation 45(3):546-553
39. Decochez K, Keymeulen B et al. (2000) Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry. Diabetes Care 23(8):1072-1078
40. Dotta F, Dionisi S et al. (1999) T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus. Eur J Endocrinol 141(3):272-278
41. Eason JD, Cosimi AB (1999) Biologic immunosuppressive agents. In: Ginns L, Cosimi A, Morris P (eds) Transplantation. Blackwell, Malden, USA, pp 196-224
42. Elias D, Cohen IR (1994) Peptide therapy for diabetes in NOD mice. Lancet 343(8899):704-706
43. Elias D, Meilin A et al. (1997) Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 46(5):758-764
44. Elias D, Reshef T et al. (1991) Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci USA 88(8):3088-3091
45. Feutren G, Papoz L et al. (1986) Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 2(8499):119-124
46. French MB, Allison J et al. (1997) Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes 46(1):34-39
47. Friend PJ, Hale G et al. (1999) Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68:1632-1637
48. Fujino-kurihara H, Fujita H et al. (1985) Morphological aspects on pancreatic islets of non-obese diabetic (NOD) mice. Virchows Arch B Cell Pathol Incl Mol Pathol 49(2):107-120
49. Garchon HJ, Bedossa P et al. (1991) Identification and mapping to chromosome 1 of a susceptibility locus for periinsulitis in non-obese diabetic mice. Nature 353(6341):260-262
50. Gomez-Reino JJ, Carmona L et al. (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: amulticenter activesurveillance report. Arthritis Rheum 48(8):2122-2127
51. Harrison LC, Honeyman MC et al. (1997) A peptide-binding motif for I-A(g7), the class II major histocompatibility complex (MHC) molecule of NOD and Biozzi AB/H mice. J Exp Med 185(6):1013-1021
52. Hawkes CJ, Wasmeier C et al. (1996) Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2. Diabetes 45(9):1187-1192
53. Hayward AR, Shreiber M (1989) Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes. J Immunol 143(5):1555-1559
54. Herbelin A, Gombert JM et al. (1998) Mature mainstream TCR alpha beta(+)CD4(+) thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. J Immunol 161(5):2620-2628
55. Herold KC, Gitelman SE et al. (2005) A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54(6):1763-1769
56. Herold KC, Hagopian Wet al. (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346(22):1692-1698
57. Hirsch R, Bluestone JA et al. (1990) Anti-CD3 F(ab)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 49(6):1117-1123
58. Honeyman MC, Cram DS et al. (1993) Glutamic acid decarboxylase 67-reactive T cells: a marker of insulin-dependent diabetes. J Exp Med 177(2):535-540
59. Humphreys Beher MG, Brinkley L et al. (1993) Characterization of antinuclear autoantibodies present in the serum from nonobese diabetic (NOD) mice. Clin Immunol Immunopathol 68(3):350-356
60. Katz JD, Wang B et al. (1993) Following a diabetogenic T cell from genesis through pathogenesis. Cell 74(6):1089-1100
61. Keane J, Gershon S et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098-1104
62. Keymeulen B, Vandemeulebroucke E et al. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352(25):2598-2608
63. Kohm AP, Williams JS et al. (2005) Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 174(8):4525-4534
64. Kung P, Goldstein G et al. (1979) Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206(4416):347-349
65. Lampasona V, Bearzatto M et al. (1996) Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol 157(6):2707-2711
66. Langer-Gould A, Atlas SW et al. (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353(4):375-381
67. Leo O, Foo M et al. (1987) Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 84(5):1374-1378
68. Lepault F, Gagnerault MC (2000) Characterization of peripheral regulatory CD4(+) T cells that prevent diabetes onset in nonobese diabetic mice. J Immunol 164(1):240-247
69. Lieberman SM, Evans AM et al. (2003) Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci USA 100(14):8384-8388
70. Ludviksson BR, Ehrhardt RO et al. (1997) TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J Immunol 159(7):3622-3628
71. Mahiou J, Walter U et al. (2001) In vivo Blockade of the Fas-Fas Ligand Pathway Inhibits Cyclophosphamide-induced Diabetes in NOD Mice. J Autoimmun 16(4):431-440
72. Maki T, Ichikawa T et al. (1992) Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci USA 89(8):3434-3438
73. Makino S, Kunimoto K et al. (1980) Breeding of a non-obese, diabetic strain of mice. Exp Anim 29(1):1-13
74. Many MC, Maniratunga S et al. (1996) The non-obese diabetic (NOD) mouse: An animal model for autoimmune thyroiditis. Exp Clin Endocrinol Diabetes 104:17-20
75. Many MC, Maniratunga S et al. (1995) Two-step development of Hashimoto-like thyroiditis in genetically autoimmune prone non-obese diabetic mice: effects of iodine-induced cell necrosis. J Endocrinol 147(2):311-320
76. Nakhooda AF, Like AA et al. (1977) The spontaneously diabetic Wistar rat. Metabolic and morphologic studies. Diabetes 26(2):100-112
77. Nicolls MR, Aversa GG et al. (1993) Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 55(3):459-468
78. Nishizuka Y, Sakakura T (1969) Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 166(906):753-755
79. Noorchashm H, Noorchashm N et al. (1997) B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 46(6):941-946
80. Ohsugi T, Kurosawa T (1994) Increased incidence of diabetes mellitus in specific pathogeneliminated offspring produced by embryo transfer in NOD mice with low incidence of the disease. Lab Anim Sci 44(4):386-388
81. Ortho Multicenter Transplant Study Group (1985) A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313(6):337-342
82. Panina-bordignon P, Lang R et al. (1995) Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med 181(5):1923-1927
83. Parlevliet KJ, Ten Berge IJ et al. (1994) In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest 93(6): 2519-2525
84. Plain KM, Chen J et al. (1999) Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy. Transplantation 67(4):605-613
85. Quezada SA, Jarvinen LZ et al. (2004) CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 22:307-328
86. Rohane PW, Shimada A et al. (1995) Islet-infiltrating lymphocytes from prediabetic NOD mice rapidly transfer diabetes to NOD-scid/scid mice. Diabetes 44(5):550-554
87. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6(4):345-352
88. Salomon B, Lenschow DJ et al. (2000) B7/CD28 Costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431-440
89. Sempe P, Bedossa P et al. (1991) Anti-alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice. Eur J Immunol 21(5):1163-1169
90. Serreze DV, Chapman HD et al. (1996) B lymphocytes are essential for the initiation of T cellmediated autoimmune diabetes: Analysis of a new "speed congenic" stock of NOD.Ig mu(null) mice. J Exp Med 184(5):2049-2053
91. Serreze DV, Silveira PA (2003). The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes. Curr Dir Autoimmun 6:212-227
92. Shoda LK, Young DL et al. (2005) A Comprehensive Review of Interventions in the NOD Mouse and Implications for Translation. Immunity 23(2):115-126
93. Smith JA, Tang Q et al. (1998) Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 160(10):4841-4849
94. Smith JA, Tso JY et al. (1997) Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 185(8):1413-1422
95. Sreenan S, Pick AJ et al. (1999) Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 48(5):989-996
96. Strandell E, Eizirik DL et al. (1990) Reversal of beta-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus. J Clin Invest 85(6):1944-1950
97. Tisch R, Yang XD et al. (1994) Administering glutamic acid decarboxylase to NOD mice prevents diabetes. J Autoimmun 7(6):845-850
98. Trembleau S, Penna G et al. (1997) Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur J Immunol 27(9):2330-2339
99. Utsugi T, Yoon JW et al. (1996) Major histocompatibility complex class I-restricted infiltration and destruction of pancreatic islets by NOD mouse-derived beta-cell cytotoxic CD8(+) T-cell clones in vivo. Diabetes 45(8):1121-1131
100. Van Assche G, Van Ranst M et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohns disease. N Engl J Med 353(4):362-368
101. Van Lier RA, Boot JH et al. (1987) Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems. Eur J Immunol 17(11):1599-1604
102. Vigeral P, Chkoff N et al. (1986) Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. Transplantation 41(6):730-733
103. Waldmann H, Cobbold S (1998) How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol 16:619-644
104. Wegmann DR (1996) The immune response to islets in experimental diabetes and insulindependent diabetes mellitus. Curr Opin Immunol 8(6):860-864
105. Wegmann DR, Norbury-glaser M et al. (1994) Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol 24(8):1853-1857
106. Wekerle T, Kurtz J et al. (2002) Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 14(5):592-600
107. Wesselborg S, Janssen O et al. (1993) Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 150(10):4338-4345
108. Wicker LS, Miller BJ et al. (1986) Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes 35(8):855-860
109. Wong JT, Colvin RB (1991) Selective reduction and proliferation of the CD4+ and CD8+ T cell subsets with bispecific monoclonal antibodies: evidence for inter-T cell-mediated cytolysis. Clin Immunol Immunopathol 58(2):236-250
110. Wood ML, Monaco AP et al. (1971) Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing. Transplant Proc 3(1):676-679
111. Woodle ES, Xu D et al. (1999) Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68(5):608-616
112. Yasunami R, Bach JF (1988) Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol 18(3):481-484
113. Yasunami R, Debray-sachs M et al. (1990) Ontogeny of regulatory and effector T cells in autoimmune NOD mice. In: Shafrir E (eds) Frontiers in diabetes research. Lessons from animal diabetes III. vol 19, Smith-Gordon, London pp 88-93
114. You S, Belghith M, et al. (2005) Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T cells. Diabetes 54:1415-1422
115. You S, Leforban B, et al. (2007) Adaptive TGF-{beta}-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci USA 104(15):6335-6340
116. You S, Thieblemont N, et al. (2006) Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol Rev 212:185-202